No Data
No Data
No Data
No Data
No Data
Matilda Biotech (002932.SZ): Net profit of 32.0521 million yuan in the first quarter decreased by 57.52% year-on-year
On April 29, Ge Longhui (002932.SZ) released its report for the first quarter of 2024. Operating income for the reporting period was 609.634 million yuan, down 83.63% year on year; net profit attributable to shareholders of listed companies was 32.5521 million yuan, down 57.52% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss - 15.9706 million yuan; basic earnings per share of 0.14 yuan.
Gelonghui FinanceApr 29 04:55 ET
Mingde Biotech (002932.SZ): 1.32% of shares have been repurchased cumulatively
Gelonghui, April 16, 丨 Matilda Biotech (002932.SZ) announced that up to April 16, 2024, the company had repurchased 3,069,596 shares of the company through a dedicated securities account, accounting for 1.32% of the company's total share capital; the highest transaction price for repurchased shares was 20.98 yuan/share, the minimum transaction price was 19.41 yuan/share, and the total transaction amount was RMB 62,016,952.69 (excluding transaction taxes and fees).
Gelonghui FinanceApr 16 06:34 ET
Matilda Biology (002932.SZ): Dengue fever testing products already used in public health
Gelonghui, April 12 | Mingde Biotech (002932.SZ) said on the investor interactive platform that the company already has dengue fever testing products used in public health.
Gelonghui FinanceApr 12 05:43 ET
Mingde Biotech (002932.SZ): No products related to quantum dot liquid biochips
Gelonghui, March 29丨Mingde Biotech (002932.SZ) said on the investor interactive platform that the company has no products related to quantum dot liquid biochips, and that the company already has related products and layouts in electrochemical chips, multi-protein chips, etc.
Gelonghui FinanceMar 29 05:11 ET
Mingde Biotech (002932.SZ): Initial repurchase of 500,000 shares involving 9.944 million yuan
On March 27, Ge Longhui (002932.SZ) announced that on March 27, 2024, the company repurchased 500,000 shares of the company's shares through a dedicated securities account through centralized bidding, accounting for 0.215% of the company's total share capital; the highest transaction price of the repurchased shares was 20 yuan/share, the minimum transaction price was 19.69 yuan/share, and the total transaction amount was RMB 9.944 million (excluding transaction tax).
Gelonghui FinanceMar 27 05:44 ET
Matilda Biotech (002932.SZ): Actively laying out the application of AI in the field of CDSS
Gelonghui, March 26 | Mingde Biotech (002932.SZ) said on the investor interactive platform that the company is building a comprehensive solution for smart hospital testing, including molecular, blood gas, immunity, blood coagulation and other instruments and an information-based testing system for critical illness, as well as the development and production of wearable devices for patients. At the same time, the company is actively deploying AI in the field of CDSS (Clinical Decision Support System), mainly focusing on patient management, risk prediction, diagnosis and treatment assistance, treatment suggestions, case management, etc., to provide patients with more accurate and personalized decision support and improve the quality and efficiency of medical services.
Gelonghui FinanceMar 26 05:29 ET
No Data
No Data